Fairness opinions › Acquirers
Thermo Fisher Scientific: healthcare acquisitions with fairness opinions
5 public-company targets, 2010-2023, $37B combined enterprise value. The multiples Thermo Fisher Scientific paid and the banker analyses behind each target board's recommendation.
Deals
5
Median EV / EBITDA paid
17.8x
Median EV / revenue paid
3.83x
| Announced | Target | Acquirer | Segment | EV | EV/EBITDA | EV/Rev | DCF rate | Fairness opinion |
|---|---|---|---|---|---|---|---|---|
| 2023-10-17 | Olink Holding AB | Thermo Fisher Scientific | Diagnostics / Life Sciences | $3.0B | 591.4x | 14.79x | 10.5%–11.5% | J.P. Morgan, Goldman Sachs |
| 2021-04-15 | PPD | Thermo Fisher Scientific | Pharmaceutical Services | $20B | 20.3x | 3.83x | 7.5%–8.5% | J.P. Morgan |
| 2017-05-15 | Patheon NV | Thermo Fisher Scientific | Pharmaceutical Services | $7.4B | 16.4x | 3.66x | 7.7%–8.9% | Morgan Stanley |
| 2016-05-27 | FEI | Thermo Fisher Scientific | Diagnostics / Life Sciences | $4.1B | 15.1x | 3.73x | 9.5%–11.5% | Goldman Sachs |
| 2010-12-13 | Dionex | Thermo Fisher Scientific | Diagnostics / Life Sciences | $2.0B | 17.8x | 4.44x | 8.0%–10.0% | Goldman Sachs |